Equity Bancshares, Inc. (EQBK) Forms $35.93 Double Top; Iridex (IRIX) Has 0.55 Sentiment

Equity Bancshares, Inc. (EQBK) formed double top with $38.80 target or 8.00% above today’s $35.93 share price. Equity Bancshares, Inc. (EQBK) has $439.57M valuation. The stock increased 1.18% or $0.42 during the last trading session, reaching $35.93. About 1,248 shares traded. Equity Bancshares, Inc. (NASDAQ:EQBK) has risen 37.05% since January 4, 2017 and is uptrending. It has outperformed by 20.35% the S&P500.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $96.11 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

Since January 1, 0001, it had 1 insider buy, and 0 sales for $39,200 activity.

The stock increased 0.24% or $0.02 during the last trading session, reaching $8.3. About 74 shares traded. IRIDEX Corporation (IRIX) has declined 35.41% since January 4, 2017 and is downtrending. It has underperformed by 52.11% the S&P500.

Analysts await IRIDEX Corporation (NASDAQ:IRIX) to report earnings on March, 14. They expect $-0.21 EPS, down 90.91% or $0.10 from last year’s $-0.11 per share. After $-0.27 actual EPS reported by IRIDEX Corporation for the previous quarter, Wall Street now forecasts -22.22% EPS growth.

Paragon Associates & Paragon Associates Ii Joint Venture holds 10% of its portfolio in IRIDEX Corporation for 1.25 million shares. Acuta Capital Partners Llc owns 2.00 million shares or 3.36% of their US portfolio. Moreover, Lyon Street Capital Llc has 1.6% invested in the company for 442,647 shares. The Minnesota-based Perkins Capital Management Inc has invested 0.87% in the stock. First Light Asset Management Llc, a Minnesota-based fund reported 238,795 shares.